Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
As global markets navigate a complex landscape of economic resilience and inflationary pressures, Asian equities have shown mixed performance amid these shifting dynamics. For investors interested in smaller or newer companies, penny stocks—despite the term's somewhat outdated nature—remain a compelling area for potential growth. These stocks, often characterized by their affordability and growth potential when supported by robust financials, can offer intriguing opportunities; this article...
DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) (“ImmuneOnco”) have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M (“Termination Agreement”). Under the terms of the Termination Agr
First patient dosed in Phase 1 clinical trial evaluating AXN-2510/IMM2510 (“’2510”) monotherapy in adult patients with advanced solid tumorsDALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its third quarter 2025 financial results and provided a corporate update.Recent Highlights:In September, ImmuneOnco, Instil’s collaborator, presented updated data f
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.